91660-72-9

Upstream product

• 13616-37-0 ethyl (tetrazol-5-yl)acetate 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 937058-05-4 methyl 3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]propanoate 
• 937051-13-3 3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]propionic acid 
• 937058-04-3 3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]propionitrile 
• 937058-03-2 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]ethyl methanesulfonate 
• 937058-02-1 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-1-ethanol 
• 475062-22-7 carbamic acid 1-(8-(4-tert-butyl-thiazol-2-ylcarbamoyl)-3-{2-[2-(4-methoxy-benzyl)-2H-tetrazol-5-yl]-vinyl}-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)-piperidin-3-yl ester 
• 475062-21-6 2-(3-hydroxy-piperidin-1-yl)-3-{2-[2-(4-methoxy-benzyl)-2H-tetrazol-5-yl]-vinyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxylic acid (4-tert-butyl-thiazol-2-yl)-amide 

Relevant academic research and scientific papers

Drug efflux pump inhibitor

A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH═CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)═C(R9)— (R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

A reagent, ethyl 2-(2-tert-butyl-2H-tetrazol-5-yl)-3-(dimethylamino)acrylate (DMTE), for facile synthesis of 2,3-(ring fused)-5-(5-tetrazolyl)-4H-pyrimidin-4-one derivatives

A method for synthesizing 2,3-(ring fused)-5-(5-tetrazolyl)-4H-pyrimidin-4-one derivatives from ethyl 2-(2-tert-butyl-2H-tetrazol-5-yl)-3-(dimethylamino)acrylate (DMTE) (4a) and amino-heterocycles is described. The structure of DMTE, which was prepared from ethyl (2-tert-butyl-2H-tetrazol-5-yl)acetate (3a) with dimethylformamide diethylacetal, was determined by X-ray analysis to be Z form. The reaction of 2-amino-5-methyloxazole (6) with DMTE in acetic acid gave the oxazolo[3,2-a]pyrimidine derivative (8), heating of which in concentrated sulfuric acid afforded the desired tetrazole derivative (20). Pyrimido[2,1-b]benzothiazole (21), pyrazolo[1,5-a]pyrimidine (22 and 23) and [1,2,4]triazolo[1,5-a]pyrimidine (24) derivatives were prepared in a similar manner.